Effect of Combination Therapy with Alpha-Lipoic Acid on the Fractalkine Level in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus
Journal Title: Міжнародний ендокринологічний журнал - Year 2016, Vol 7, Issue 79
Abstract
Background. The aim of research — to assess the fractalkine levels in patients with coronary artery disease (CAD), depending on the presence of type 2 diabetes mellitus (DM) and the nature of coronary artery lesions before treatment and during the standard and combination therapy with the addition of alpha-lipoic acid. Materials and methods. We have examined 131 patients with CAD (89 men and 42 women), mean age of them was 59.60 ± 9.11 years. The control group consisted of 20 apparently healthy volunteers of the same age and sex. Depending on the presence of type 2 DM, patients with CAD were divided into 2 groups: the first group (n = 70) — patients with concomitant type 2 DM, the second group (n = 61) — patients with CAD and without concomitant type 2 DM. All patients were performed coronary angiography to verify the diagnosis of CAD. All patients, depending on the nature of coronary artery lesions and therapy, were divided into 2 subgroups — subgroup IA (standard therapy) and the subgroup IB (combination therapy). All patients were evaluated fractalkine levels before therapy and after 3 months of treatment. Results. The study found that patients with CAD, both with concomitant type 2 DM or without it, had significantly increased levels of fractalkine compared with the control group (p < 0.05). When comparing treatment regimens, it was found that in the subgroup of standard therapy, fractalkine average level before treatment was 485.07 ± 106.55 pg/ml, and after 3 months of therapy — 444.08 ± 99.86 pg/ml, while there was no significant difference between baseline value and the value reached after 3 months (p = 0.08), although there was a trend to reduce the level of this indicator. Patients from IB subgroup (n = 105), who received combination therapy, had a significant trend to reduce the fractalkine level in 3 months as compared to the initial value before therapy (510.49 ± 103.95 pg/ml vs 575.56 ± 123.86 pg/ml; p = 0.00001). The relative reduction in fractalkine level in the subgroup IA was 8.45 %, in the subgroup IB — 11.3 %. Conclusions. The study results demonstrate the impact of endothelial dysfunction on the development and progression of atherosclerosis, especially in patients with concomitant type 2 DM. Applying alpha-lipoic acid in combination therapy schemes contributes to a significant reduction in fractalkine levels, and, thus, leads to a decrease in endothelial dysfunction and, as a result, to the possible improvement of prognosis in this group of patients.
Authors and Affiliations
L. V. Zhuravlyova, N. A. Lopina
Keywords
Related Articles
- EP ID EP177638
- DOI 10.22141/2224-0721.7.79.2016.86422
- Views 67
- Downloads 0
On the Scientific Popularization of Knowledge about Diabetes (Problems and Judgments)
.
Pathogenetic significance of proinflammatory cytokines and dyslipidemia in the development of cardiovascular complications in patients with hypothyroidism
Background. The manifestation of violations in the morphofunctional state of the cardiovascular system is on one of the first places in the symptomatology of hypothyroidism, which is associated with various direct and in...
A Case of Pasqualini Syndrome
The article presents a case of isolated congenital deficiency of luteinizing hormone (Pasqualini syndrome) that manifested by secondary hypogonadism with abnormalities of copulative and fertile functions, which were norm...
Evaluating the efficiency of surgical treatment of ACTH-dependent Cushing’s syndrome in the early and late postoperative period
Background. Adrenocorticotropic hormone-dependent Cushing’s syndrome (ACTH-dependent CS) is a form of endogenous CS caused by abnormal production of ACTH, in 80 % of cases — due to ACTH oversecretion by a pituitary adeno...
New Therapeutic Possibilities of Type 2 Diabetes Mellitus Management: Experience of Voglibose Application
Objective of the study — an estimation of efficiency of application and tolerability of new alpha-glucosidase inhibitor voglibose (Voxid) in the treatment of patients with type 2 diabetes mellitus (DM). Material and Meth...